FDA 发布 Q1A(R2) 新药原料药和产品稳定性试验指南第二次修订版

Q1A(R2) Stability Testing of New Drug Substances and Products

AI 导读

FDA 发布 Q1A(R2) 新药原料药和产品稳定性试验指南第二次修订版，目的是把气候带 I 和 II 的中间储存条件与 ICH Q1F 中气候带 III 和 IV 推荐的长期条件相协调。该指南首次发布于 1994 年 9 月，2001 年 8 月修订，本次修改内容列于指南附件。文件为最终指南，文号 FDA-2002-D-0222，由 CDER 和 CBER 发布。

推荐理由

材料说明了 Q1A(R2) 第二次修订的协调目的，即统一气候带 I、II 的中间储存条件与 Q1F 中 III、IV 带的长期条件。

正文 · 原文

GUIDANCE DOCUMENT

Final

Docket Number:

FDA-2002-D-0222

Issued by:

Guidance Issuing Office

Center for Drug Evaluation and Research

Center for Biologics Evaluation and Research

This guidance is the second revision of Q1A Stability Testing of New Drug Substances and Products, which was first published in September 1994 and revised in August 2001. The purpose of this revision is to harmonize the intermediate storage condition for zones I and II with the long-term condition for zones III and IV recommended in the ICH guidance Q1F Stability Data Package for Registration Applications in Climatic Zones III and IV. The changes made in this second revision are listed in the attachment to this guidance.

Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2002-D-0222.